沉默酰基辅酶A-胆固醇酰基转移酶1基因对人前列腺癌细胞生物学行为的影响

Abstract
Figure/Table
References (20)
Related Citation (10)

Download: PDF (926 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the effect of ACAT1 on human prostate cancer cells proliferation, invasion and migration. Methods Human prostate cancer cells (PC-3 cells) were cultured, then the expression of ACAT1 gene in PC-3 cells were interfered using Hiperfect transfection reagent, the expression of ACAT1 gene before and after transfection was detected by Real-time PCR. The proliferation rates of PC-3 cells in the blank control group (serum-free 1640 medium added), the negative control group (negative-siRNA-HiperFect complex added) and the ACAT1 group (ACAT1 siRNA-HiperFect complex added) were analyzed by CFSE staining. The changes of cell proliferation before and after ACAT1 gene silencing were compared. Transwell assays were used to evaluate the effect of ACAT1 gene interfering on cells migration and invasion. Results Compared with the blank control group and the negative control group respectively, ACAT1 mRNA expression level reached the lowest level after 48 hours in the ACAT1 siRNA group (P < 0.05). In the ACAT1 siRNA group, compared with the blank control group and the negative control group, proliferation rate of PC-3 cell decreased, the numbers of invasive cell and migration cell reduced, the differences were statistically significant (P < 0.01). Compared between the blank control group and the negative control group, the differences in proliferation rate, invasion and migration ability of human prostate cancer PC-3 cells had no statistically significant (P > 0.05). Conclusion ACAT1 siRNA reduces proliferation, migration and invasion of PC-3 cells, which maybe provide a new idea and strategy for pathogenesis and treatment of prostate cancer.

Key words： Prostate cancer Acyl coenzyme A cholesterol acyltransferase 1 Small interference RNA Biology behaviors

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Xin1 XU Ximing1 GAN Yuanyuan1 CAO Dedong1 WU Long1 CHEN Zhiyuan2

Cite this article:

CHEN Xin1 XU Ximing1 GAN Yuanyuan1 CAO Dedong1 WU Long1 CHEN Zhiyuan2. Effect of ACAT1 gene knockdown on the biological behavior of the prostate cancer cells[J]. 中国医药导报, 2017, 14(22): 4-7,15.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2017/V14/I22/4

[1] Siegel RL，Miller KD，Jemal A. Cancer statistics，2015 [J]. CA Cancer J Clin，2015，65（1）：5-29.
[2] 刘芳，王依洁，单雄威，等.2型糖尿病对前列腺癌发病风险和预后的影响[J].临床泌尿外科杂志，2016，31（10）：946-949.
[3] Pelton K，Freeman MR，Solomon KR. Cholesterol and prostate cancer [J]. Curr Opin Pharmacol，2012，12（6）：751-759.
[4] Krycer JR，Brown AJ. Cholesterol accumulation in prostate cancer： a classic observation from a modern perspective [J]. Biochim Biophys Acta，2013，1835（2）：219-229.
[5] Bhindi B，Locke J，Alibhai SM，et al. Dissecting the association between metabolic syndrome and prostate cancer risk： analysis of a large clinical cohort [J]. Eur Urol，2015， 67（1）：64-70.
[6] Moon H，Ruelcke JE，Choi E，et al. Diet-induced hypercholesterolemia promotes androgen-independent prostate cancer metastasis via IQGAP1 and caveolin-1 [J]. Oncotarget，2015，6（10）：7438-7453.
[7] Saraon P，Cretu D，Musrap N，et al. Quantitative proteomics reveals that enzymes of the ketogenic pathway are associated with prostate cancer progression [J]. Mol Cell Proteomics，2013，12（6）：1589-1601.
[8] Ribas V，Garcia-Ruiz C，Fernandez-Checa JC. Mitochondria，cholesterol and cancer cell metabolism [J]. Clin Transl Med，2016，5（1）：22.
[9] Platz EA，Till C，Goodman PJ，et al. Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial [J]. Cancer Epidemiol Biomarkers Prev，2009，18（11）：2807-2813.
[10] Morote J，Celma A，Planas J，et al. Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness [J]. Int J Mol Sci，2014，15（8）：13615-13623.
[11] Schnoeller TJ，Jentzmik F，Schrader AJ，et al. Influence of serum cholesterol level and statin treatment on prostate cancer aggressiveness [J]. Oncotarget，2017. [Epub ahead of print].
[12] Batty GD，Kivimaki M，Clarke R，et al. Modifiable risk factors for prostate cancer mortality in London： forty years of follow-up in the Whitehall study [J]. Cancer Causes Control，2011，22（2）：311-318.
[13] Bansal D，Undela K，D'cruz S，et al. Statin use and risk of prostate cancer： a meta-analysis of observational studies [J]. PLoS One，2012，7（10）：e46691.
[14] Ghosh S. Early steps in reverse cholesterol transport： cholesteryl ester hydrolase and other hydrolases [J]. Curr Opin Endocrinol Diabetes Obes，2012，19（2）：136-141.
[15] Antognelli C，Ferri I，Bellezza G，et al. Glyoxalase 2 drives tumorigenesis in human prostate cells in a mechanism involving androgen receptor and p53-p21 axis [J]. Mol Carcinog，2017. [Epub ahead of print]. DOI：10.1002/ mc.22668.
[16] Garcia-Bermudez J，Birsoy K. Drugging ACAT1 for Cancer Therapy [J]. Mol Cell，2016，64（5）：856-857.
[17] Yang W，Bai Y，Xiong Y，et al. Potentiating the antitumour response of CD8（+）T cells by modulating cholesterol metabolism [J]. Nature，2016，531（7596）：651-655.
[18] Uda S，Accossu S，Spolitu S，et al. A lipoprotein source of cholesteryl esters is essential for proliferation of CEM-CCRF lymphoblastic cell line [J]. Tumour Biol，2012，33（2）：443-453.
[19] Li J，Lee SY，Gu D，et al. Abstract B50：Abrogating cholesterol esterification suppresses pancreatic cancer growth and metastasis mediated by caveolin-1 [J]. Cancer Res，2015，75（13 Supplement）：B50.
[20] Ye K，Wu Y，Sun Y，et al. TLR4 siRNA inhibits proliferation and invasion in colorectal cancer cells by downregulating ACAT1 expression [J]. Life Sci，2016，155（2016）： 133-139.